Nova Patents
AT326265T

Combination of dhea and calcitonin for the treatment of subnormal bone mineral density

Abstract

The invention claims for treating individual to increasing individual the bone mineral substance density (BMD) method. The method comprises a feeder and serum calcium element type reagent and DHEA type a reagent. The invention further claims the reinforcing portion serum the calcium element type reagent to the BMD treating result, and increasing the channels DHEA treating individual the method of BMD, for example for treating systemic lupus erythematosus.

Term

No projected expiry on record.

  1. Priority
  2. Filed
  3. Granted
  4. Today

28 members in 18 offices

This recordMember, by publication datePriority claim8 more offices are in the list below

Priority claims8

Priority claims
DocumentOfficeKindDate
16508999United States of AmericaP
16508999United States of AmericaP
71072900United States of AmericaA
71072900United States of AmericaA
165089P–––
710729–––
US19990165089P–––
US20000710729–––

Members28

Family members, oldest first
DocumentOfficeKind
CA2390431A1CanadaA1
WO0135975A2World Intellectual Property Organization (WIPO)A2
AU1580201AAustraliaA
WO0135975A3World Intellectual Property Organization (WIPO)A3
NO20022246D0NorwayD0
BR0015534ABrazilA
NO20022246LNorwayL
KR20020063183ARepublic of KoreaA
EP1231983A2European Patent Office (EPO)A2
IL149532A0IsraelA0
IL149532D0IsraelD0
MXPA02004776AMexicoA
JP2003514026AJapanA
CN1411386AChinaA
ZA200203527BSouth AfricaB
US6605591B1United States of AmericaB1
US2003158159A1United States of AmericaA1
RU2002115815ARussian FederationA
NZ518791ANew ZealandA
US6854468B2United States of AmericaB2
TWI228992BTaiwan Province of ChinaB
US2005113301A1United States of AmericaA1
AU784160B2AustraliaB2
EP1231983B1European Patent Office (EPO)B1
AT326265TThis recordAustriaT
ATE326265T1AustriaT1
DE60028074D1GermanyD1
US7612034B2United States of AmericaB2